Collaboration represents one of the first efforts to apply nanotechnology to molecularly targeted cancer therapies
At AstraZeneca, we believe that targeted therapies that specifically address the underlying mechanisms of disease are the future of personalised cancer treatment. In the oncology area, our teams are actively exploring a range of platforms to deliver targeted therapies, with a strategic focus on unlocking the significant potential of nanoparticles in cancer treatment. We do this through our internal research as well as through partnerships with leading scientists across the globe.
In April 2013, our Oncology Innovative Medicines Unit announced a strategic collaboration with BIND Therapeutics, a clinical-stage nanomedicine company. Our joint goal is to develop and commercialise a nanomedicine using BIND’s ACCURIN technology platform and AstraZeneca’s targeted Aurora B kinase inhibitor AZD2811.
The joint team has made great progress and just published their first scientific paper. The manuscript describes how the team developed the first nanoparticle preclinical candidate, through careful characterisation of efficacy, safety, pharmacokinetics and distribution in preclinical models.
Previous efforts with nanotechnology have primarily focused on encapsulating chemotherapy payloads. But the data generated by our collaboration with BIND highlight the ability of ACCURINS®, a polymeric nanoparticle technology, to utilise hydrophobic ion pairing and to improve the therapeutic index of a molecularly targeted anti-cancer drug.
The results demonstrate the ability of ACCURINS® to control release kinetics and maintain a high concentration of an aurora B kinase inhibitor (AZD2811) at tumour sites in preclinical models. This enabled prolonged pharmacodynamic effects, superior tumour growth inhibition and a reduction in off-tissue toxicities.